Call for Abstracts
The 58th Annual Meeting of Liver Cancer Study Group of Japan is open for overseas doctors to submit their abstracts. We look forward to your submissions.
Submission period
Friday, January 28, 2022 – Noon, Wednesday, February 16, 2022 (In Japan Standard Time)
Regarding abstract submission
You may submit your abstract to either “theme session” or “general presentation session”.
1. Topics for abstracts
Authors must select a category that best fits the subject of their abstract. The Program Committee reserves the right to recategorize abstracts.
If you wish to submit abstract to “theme session”
Please select one from 1-24 in the table below.
| 1 | Symposium1 | Establishment of the new HCC surveillance model, focusing on the screening of non-viral chronic liver disease |
|---|---|---|
| 2 | Symposium2 | Evolving treatment strategies for Intermediate stage HCC |
| 3 | Symposium3 | A challenge to metastatic liver cancer |
| 4 | Symposium4 | Systemic medical therapy and combination/conversion treatment (hepatectomy, ablation, TACE etc.) |
| 5 | Symposium5 | Construction of new liver cancer treatment models using big data, artificial intelligence and the internet of things |
| 6 | Panel discussion1 | New development of imaging diagnosis of liver cancer |
| 7 | Panel discussion2 | Hepatic carcinogenesis and cancer treatment in NAFLD/NASH |
| 8 | Panel discussion3 | Evolution of tumor ablation (expand indication, assessment of ablative margin, new devices, etc.) |
| 9 | Panel discussion4 | Treatment strategies for recurrent hepatocellular carcinoma |
| 10 | Panel discussion5 | Aiming to improve treatment outcomes of immunotherapy for hepatocellular carcinoma |
| 11 | Panel discussion6 | Precision oncology in liver cancer (using genome, panel testing, liquid biopsy and gene signature etc.) |
| 12 | Panel discussion7 | Recent advances in techniques of liver resection (navigation, simulation, laparoscopic surgery, robot surgery etc.) |
| 13 | Panel discussion8 | Resectable, borderline resectable and unresectable in liver cancer |
| 14 | Panel discussion9 | Diagnosis and treatment of intrahepatic cholangiocarcinoma |
| 15 | Workshop1 | Current status of the significance and indications of liver tumor biopsy |
| 16 | Workshop2 | Liver cancer treatment after hepatitis virus control |
| 17 | Workshop3 | Tasks and measures of ablation for obese patients |
| 18 | Workshop4 | New development of liver transplantation |
| 19 | Workshop5 | New direction of transarterial treatment: TACE, HAIC, etc. |
| 20 | Workshop6 | New development of radiation therapy |
| 21 | Workshop7 | Nurturing the younger generation on liver cancer treatment (surgical treatment, ablation, endovascular treatment etc.) |
| 22 | Video workshop1 | How I do it（Surgical treatment） |
| 23 | Video workshop2 | How I do it（Ablation） |
| 24 | Video workshop3 | How I do it（Vascular intervention） |
If you wish to submit abstract to “general presentation session”
Please select one from 1-23 in the table below.
| 1 | Diagnostic imaging |
|---|---|
| 2 | Tumor markers / Biomarkers / Liquid biopsy |
| 3 | Assessment of liver function |
| 4 | Hepatocellular carcinoma and Antiviral therapy |
| 5 | Viral hepatitis-related hepatocellular carcinoma |
| 6 | Non-B, non-C hepatocellular carcinoma (NBNC HCC) |
| 7 | Intermediate-stage hepatocellular carcinoma |
| 8 | Advanced hepatocellular carcinoma |
| 9 | Intrahepatic cholangiocarcinoma |
| 10 | Combined hepatocellular-cholangiocarcinoma and cholangiolocellular carcinoma |
| 11 | Metastatic liver cancer |
| 12 | Hepatectomy |
| 13 | Liver transplantation |
| 14 | Ablation (radiofrequency ablation, microwave ablation) |
| 15 | Vascular intervention |
| 16 | Systemic therapy (molecular targeted agent) |
| 17 | Systemic therapy (immune checkpoint inhibitor) |
| 18 | Systemic therapy (adverse events) |
| 19 | Systemic therapy (case report) |
| 20 | Radiation therapy (including heavy particle therapy) |
| 21 | Pathology |
| 22 | Basic research |
| 23 | Others |
2. Type of presentation
Oral presentation only
3. Abstract submission guideline
(1) Maximum number of authors and affiliations allowed to register:
- Up to 20 persons including the first author
- Up to 10 affiliations
(2) Word Limitation
- Abstract title: Within 100 single-byte characters
- Abstract body: Within 1,800 single-byte characters
- Total number of characters: Within 2,800 single-byte characters (Including name of affiliation, authors, abstract title and abstract body)
*You cannot submit your data exceeding the word limitation above
*Space is counted as 1 single-byte character - You cannot insert any image/diagram
4. Others
- You will be asked to present either on site or remotely using online meeting system
- The abstract presented during the meeting will be uploaded on the website for on-demand viewing for about a month after the meeting once the preparation is completed.
*On-demand streaming data can only be accessed by the participants of the meeting.
*Please be careful of your presentation content - use copyright free images/illustrations, make clear citations to any academic diagrams or sentences you may refer to in the abstract, and to anonymize any personal information so that they cannot be identified.
5. How to submit your abstract
Please download abstract submission form (Word file format) from the button below, fill in the required information and submit it to the secretariat via E-mail.
<Submit to E-mail address>
Secretariat of the 58th Annual Meeting of Liver Cancer Study Group of Japan
E-mail: jlcsg58-abstracts@sunpla-mcv.com
Abstract submission form